Android app on Google Play

Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss

March 6, 2012 4:01 PM EST Send to a Friend
Get Alerts ACAD Hot Sheet
Price: $19.44 --0%

Financial Fact:
Total operating expenses: 12.2M

Today's EPS Names:
FUBC, More
Trade ACAD Now!
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.

For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment